Objective. To identify the features of PMR that may predict the duration of steroid therapy, the occurrence of relapses and the late development of GCA.
Introduction
PMR is an inflammatory disease that requires treatment with systemic steroids for months or, more usually, years. Patients requiring a longer course of steroids might benefit from the earlier use of additional steroid-sparing agents or more intensive prophylaxis against steroidinduced adverse events. Duration of therapy and occurrence of relapses have been related to high baseline inflammatory markers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , older age [3] , female sex [3] , low initial steroid dose [3] , faster tapering [11] , longer duration of symptoms [12] and HLA alleles [7, 11, 13] . To our knowledge, no prospective cohort study of PMR has examined risk factors for the late development of GCA.
Our aim was to investigate clinical and genetic factors predicting outcome during 5 years of follow-up in patients with PMR. Outcomes examined were duration of steroid treatment, relapses and development of GCA in people with an initial diagnosis of PMR.
Patients and methods

Ethical approval was obtained from the local Ethics Committee [Leeds (East) Regional Ethics Committee].
Patients referred by their general practitioner (GP) with symptoms suggestive of PMR were seen by one rheumatologist (C.T.P.). Caucasians who fulfilled the Bird criteria for PMR [14] , and who gave written consent according to the Declaration of Helsinki, were consecutively enrolled in a prospective study between 1989 and 2000, with standardized data collection at presentation [including pre-treatment plasma viscosity (PV): reference range: 41.72 mPa s] and a 5-year follow-up by the same rheumatologist. Those with concomitant GCA at presentation or within the first 6 weeks of treatment were excluded. Standard steroid treatment was: 15 mg prednisolone for the first week (increased if symptoms were uncontrolled); 12.5 mg for 2 weeks; 10 mg for 6-8 weeks; and then reducing by 1 mg/month, provided the patient remained asymptomatic. The duration of steroid treatment was defined as the time between the first dose of prednisolone (whether started by the GP or by the hospital) and the end of prednisolone treatment. Relapses were defined pragmatically as an increase in activity of PMR symptoms sufficient to warrant an increase in prednisolone dose, whether by GP or hospital. HLA typing methods for this cohort have already been described [15] .
Spearman's rank correlation and Mann-Whitney U-tests were used to model predictors of the number of relapses 5 years. Cox proportional hazards regression was used to model steroid duration. Binary logistic regression was used to model the odds of relapse and of developing GCA. We entered the following variables into the regression models: age, sex, history of weight loss, baseline haemoglobin (normal or low), presence/absence of HLA-DRB1*0101 or -*0401 (both associated with PMR in this cohort [15] ), baseline PV (41.80, 1.81-1.99 or 52.00 mPa s), and initial steroid dose (415 mg/>15 mg). Variables recorded, but not included in modelling, included ESR and CRP (because they were not measured in all and because of potential collinearity with PV) and symptom duration prior to treatment (because of dependence on patient recall). For HLA, 39 individuals had missing data, and were allocated a separate code to denote this. Factors with P < 0.20 on multivariable analysis were considered potential 'predictors' to be entered into a final parsimonious model. Correction for multiple comparisons was not performed because variables were chosen based on the literature. Those lost to follow-up or who died were treated as censored in Cox regression, but were excluded from logistic regression analyses unless they had already developed relapse or GCA. Analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL, USA).
Results
A total of 201 patients were recruited: 25 were excluded because GCA was diagnosed either at the time of starting steroids or, in 3 cases, within the first 6 weeks (after 0.6, 1.86 and 3.14 weeks). GCA was confirmed by the rheumatologist (C.T.P.). Of these excluded (GCA) patients, 14 were biopsied (all positive), median baseline PV was 1.99 mPa s and mean (95% CI) duration of steroid therapy was 3.50 (2.88, 4.05) years.
One hundred and seventy-six patients had pure PMR at baseline. Mean age was 70.3 (range 53-87) years; 124 were females; median PV was 1.90 (range 1.54-2.42) mPa s; median ESR was 61.5 (range 3.0-130.0) mm/h; median CRP was 31 (range 0-167) mg/l; and 34/176 reported weight loss and 73/130 had HLA-DRB1*0101 or -*0401. In 55/176 (31.3%) patients, prednisolone had been started by the GP before the first hospital consultation (median time between starting of steroids and first hospital consultation was 3.4 months). In the rest of the patients, prednisolone was started after the patient had been seen at hospital by the rheumatologist. The cohort is described in Table 1 .
After 5 years of follow-up, out of 176 patients, 124 had stopped steroids, 5 were lost to follow-up and 7 were deceased (Fig. 1) ; none of the deaths was primarily attributable to PMR/GCA. On univariable analysis, patients in the middle or upper tertiles of baseline PV were less likely to stop steroids within 5 years than those in the lower tertile [n = 174, middle tertile hazard ratio (HR) = 0.67; 95% CI 0.44, 1.01; P = 0.057; upper tertile HR = 0.43, 95% CI 0.26, 0.71; P = 0.001; overall P = 0.005]. Other predictors of longer steroid duration were initial prednisolone dose >15 mg (n = 171; HR = 0.57; 95% CI 0.37, 0.87; P = 0.010), female sex (HR = 0.75; 95% CI 0.51, 1.10; P = 0.136) and history of weight loss (HR = 0.72; 95% CI 0.45, 1.17; P = 0.186). The initial multivariable Cox regression model (n = 151; Table 2) indicated that PV (overall P = 0.114) and initial steroid dose (P = 0.021) should be selected for inclusion in a parsimonious model. This model had significantly greater explanatory power than the null model (n = 170; À2 log likelihood = 1096.16; 2 = 15.22; df = 3; P = 0.002). High initial steroid dose independently reduced the chances of stopping steroids within a given time interval by 7% (initial prednisolone dose >15 mg; HR = 0.63; 95% CI 0.41, 0.97; P = 0.036); higher PV reduced the chances of stopping steroids by 27-51% (relative to lower tertile: middle tertile HR = 0.73; 95% CI 0.48, 1.12; P = 0.150; upper tertile HR = 0.49; 95% CI 0.29, 0.82; P = 0.006; overall P = 0.024). There was no significant interaction between PV and starting prednisolone dose. The effects of baseline PV and starting steroid dose on duration of steroid therapy are shown in Fig. 2 . Fifty-five patients ('GP-treated') were started on steroids by their GP before their first hospital appointment; thereafter steroid treatment was supervised by the rheumatologist. These patients did not differ significantly in age, sex (data not shown) or PV (median PV = 1.92 compared with 1.88 mPa s; P = 0.080). This group had a mean (95% CI) of 3.42 (3.00, 3.85) years of steroid therapy, compared with 2.59 (2.29, 2.89) years in those who started steroids after attending hospital (P = 0.021). Of the 52 patients, 33 (63.5%) were started on >15 mg by their GP, compared with 16/119 (13.4%) of those who were www.rheumatology.oxfordjournals.org started on steroids after seeing the rheumatologist (P < 0.001). Of the 16 patients who were started on >15 mg after seeing the rheumatologist, 1 needed to increase the dose of prednisolone to 20 mg because 15 mg was ineffective in treating the symptoms; 2 had disabling inflammatory polyarthropathy and were felt to require a higher initial dose of steroids; 1 was initially suspected to have GCA but this was subsequently ruled out; 2 were diagnosed and treatment was recommended by the rheumatologist but the dose was determined by the GP. The remainder were started on >15 mg because at the time there was no widespread agreement in the unit about the dosing schedule. Of the 55 GP-treated patients, 4 (7.3%) relapsed before their first hospital visit. Of the 55 GP-treated PMR patients, 9 (16.4%) developed late GCA, compared with 9/121 (7.4%) who were started on steroids after attending hospital (P = 0.181). When both PV and initial steroid dose were controlled for, whether the GP started steroids was not independently associated with duration of steroid therapy by multivariable modelling (HR = 0.82; 95% CI 0.53, 1.28; P = 0.391).
Of the 169 patients, 83 (49.1%) relapsed at least once during the 5-year follow-up period and 7 patients died or were lost to follow-up without having relapsed; 81/83 (97.6%) of relapses occurred within the first 2 years of steroid therapy. No variable predicted relapse on univariable analysis; multivariable analysis was therefore not performed. No variable predicted the number of relapses during the 5-year follow-up. Starting steroid dose was not known in three of these patients. Where a variable (i.e. PV, HLA-DRB1) has three categories, the P-value given for the reference category refers to the overall significance of that variable. OR: odds ratio. n/a: not applicable.
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Of the 176 patients, 18 developed late GCA, at a median of 14.9 (range 2.1-31.4) months after the start of treatment. We found no evidence that those who went on to develop GCA had received a lower cumulative prednisolone dose prior to the development of GCA (data not shown).
On univariable analysis (Table 2) , factors associated with an increase in the odds of late development of GCA included female sex, HLA-DRB1*0101 and -*0401, higher PV and initial prednisolone dose >15 mg. Multivariable analysis was not performed due to the small number of patients who developed GCA.
Because of the association between starting >15 mg prednisolone and development of late GCA, we added 'late development of GCA' as a factor into the model of steroid duration. When we did this, we found that 'late development of GCA' was an independently significant predictor of steroid duration (HR = 0.38; 95% CI 0.16, 0.86; P = 0.021), in addition to PV (relative to lower tertile: middle tertile HR = 0.77; 95% CI 0.51, 1.19; P = 0.242; upper tertile HR = 0.53; 95% CI 0.31, 0.89; P = 0.016; overall P = 0.055); initial dose >15 mg still retained some predictive power (HR = 0.68; 95% CI 0.44, 1.05; P = 0.083). Therefore, it seems likely that starting at >15 mg prednisolone, for a given level of baseline inflammation, may prolong the steroid therapy. Developing GCA following initiation of steroid therapy further prolongs steroid therapy, but this appears to be an independent effect.
Discussion
This prospective study with a 5-year follow-up allowed detailed analysis of factors contributing to the clinical course of PMR. Our data indicate that longer durations of steroid therapy are required in those who have higher baseline inflammatory markers, a finding consistent with existing literature [7] [8] [9] [10] [11] [12] [13] [14] . In contrast to a previous study [3] , we identified that a higher initial steroid dose was associated with prolonged duration of steroid therapy.
We were surprised by the apparently strong predictive power of the starting dose of steroids, particularly as this was independent of the level of inflammatory markers. Several potential explanations for this were considered, FIG. 2 (A) Kaplan-Meier plot of the proportion of patients who had stopped steroids, depending on the PV at presentation. (B) Kaplan-Meier plot of the proportion of patients who had stopped steroids, depending on the initial steroid dose .   FIG. 1 The number of patients still receiving steroids, off steroids, lost to follow-up or deceased at the end of each year of the study.
but neither GP initiation of steroids nor development of late GCA seemed to explain the association between starting on >15 mg prednisolone and prolonged steroid therapy. Starting on a higher dose of prednisolone might be associated with relapses caused by over-rapid tapering [11] . We did not find any positive evidence in favour of this (no association between initial steroid dose and relapses, and only four GP-treated patients relapsed prior to the first outpatient appointment), but in the absence of complete data on rates of steroid tapering by GPs, we cannot exclude over-rapid steroid tapering as a contributor to this association. Nor can we exclude over-cautious tapering by GPs. Taken together, the results of our analysis are consistent with the idea that starting >15 mg prednisolone may itself prolong steroid therapy. We speculate that this might occur via increased adrenal suppression by exogenous steroids; PMR patients already have impaired endogenous glucocorticoid production, which appears to be a feature peculiar to this disease [16] .
In our large cohort, we did not find any significant predictors of relapse. This is in contrast to some published studies [7, 8, [11] [12] [13] . We defined relapse pragmatically based on our belief that clinical history is paramount in the management of PMR; however, patient reporting of symptoms may vary according to biological, psychological and social factors, which we could not control.
Those with pure PMR at baseline who developed late GCA required the most prolonged steroid therapy; perhaps this combination of GCA and PMR leads to a combination of high steroid doses and tendency for relapse of musculoskeletal symptoms. Interestingly, the median baseline PV of this group was 2.11 mPa s, similar to that (1.99 mPa s) of the (excluded) patients with GCA at baseline, raising the question of whether these patients may have had subclinical GCA from the start. We may speculate that the independent association of late GCA with higher initial steroid doses (but still not high enough to count as adequate treatment for GCA) may have been due to a masking of GCA symptoms by these higher steroid doses; however, it is not possible to investigate this further using the current data. New imaging modalities, enabling detection of subclinical vasculitis, may shed light on this issue in future studies.
No prospective study has, to our knowledge, previously reported predictors of late GCA, and our findings are therefore of clinical interest, although conclusions must be guarded due to small numbers. In this cohort, the combination of baseline PV 5 2.0 mPa s and HLA-DRB1*0401 or -*0101 had a positive predictive value of 22% and a negative predictive value of 92% for developing late GCA.
A higher PV in PMR is associated with an increased risk of prolonged steroid therapy and late GCA. Female sex and particular HLA alleles may increase the risk of late GCA. Starting patients on >15 mg prednisolone, in this study, was associated with an adverse prognosis, both an increased the duration of steroid therapy and an increased risk of late GCA. This provides further evidence to support current management guidelines [17] .
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